Outlook Therapeutics has re-submitted its Biologics License Application (BLA) to the US Food and Drug Administration (FDA) ...

PharmAbcine's pipeline is spearheaded by olinvacimab, an antibody targeting vascular endothelial growth factor receptor 2 (VEGFR-2; also known as KDR). The VEGF/VEGFR-2 pathways are central to ...

Real world evidence from a retrospective multi-center analysis on first-line therapy for metastatic renal cell carcinoma with chromophobe histology.